PROCESSA PHARMACEUTICALS INC (PCSA)
US74275C3043 - Common Stock
In today's session, these stocks are experiencing unusual volume.
Unusual volume stocks in Wednesday's session
Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer
Phase 2 trial is an adaptive designed randomized study comparing NGC-Cap to monotherapy capecitabineResults from this Phase 2 trial will evaluate NGC-Cap’s...
Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September
HANOVER, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces that management will be participating in the...
Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri
Delivers more cancer-killing SN-38 molecules to tumor than irinotecan and Onivyde® Studies support potential benefit as an improved treatment with fewer...
PCSA Stock Earnings: Processa Pharma Misses EPS for Q2 2024
PCSA stock results show that Processa Pharma missed analyst estimates for earnings per share the second quarter of 2024.
PCSA Stock Earnings: Processa Pharma Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Processa Pharma (NASDAQ:PCSA) just reported results for the second quarter of 2...
2U (TWOU) Stock Continues to Surge in Bankruptcy Rally
2U stock is up on Tuesday with heavy trading of TWOU shares as they continue to rally following a bankruptcy filing.
Why Is Processa Pharmaceuticals (PCSA) Stock Up 29% Today?
Processa Pharmaceuticals stock is up on Tuesday as PCSA investors react to approval for a Phase 2 clinical trial of NGC-Cap.
Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer
Eight of 12 evaluable patients (66.7%) had progression-free survival (PFS) ranging from 5 to 11 months At the highest NGC-Cap dose, all three evaluable...
PCSA Stock Earnings: Processa Pharma Reported Results for Q1 2024
Processa Pharma just reported results for the first quarter of 2024.
PCSA Stock Earnings: Processa Pharma Reported Results for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Processa Pharma (NASDAQ:PCSA) just reported results for the first quarter of 20...
Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference
HANOVER, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage...
Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research
Brings extensive experience in all phases of oncology drug development HANOVER, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc....
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
HANOVER, MD, March 28, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage...
Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting
HANOVER, MD, March 25, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage...
Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
HANOVER, MD, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage...
Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference
HANOVER, MD, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage...